Clinico-pathological factors associated with radioiodine refractory differentiated thyroid carcinoma status.

Purpose: Risk factors for developing radioiodine refractory thyroid cancer (RAIR-TC) have rarely been analyzed. The purpose of the present study was to find clinical and pathological features associated with the occurrence of RAIR-disease in differentiated thyroid cancers (DTC) and to establish an effective predictive risk score.

Methods: All cases of RAIR-DTC treated in our center from 1990 to 2020 were retrospectively reviewed.

Next-Generation-Sequencing on fine needle aspirates in neck recurrence of thyroid cancers.

Objectives: Tumor molecular genotyping plays a key role in improving the management of advanced thyroid cancers. Molecular tests are classically performed on Formalin-Fixed Paraffin-Embedded (FFPE) carcinoma tissue. However alternative molecular testing strategies are needed when FFPE tumoral tissue is unavailable.

FOLFIRI in advanced platinum-resistant/refractory small-cell lung cancer: a retrospective study.

Background: Small-cell lung cancer (SCLC) accounts for approximately 15% of lung cancer and is associated with poor prognosis. In platinum-refractory or -resistant SCLC patients, few treatment options are available. Topotecan is one of the standards of care for these patients, however, due to its high toxicity, several different approaches are employed.

A meropenem pharmacokinetics model in patients with haematological malignancies.

Background: Optimal dosing of antibiotics is critical in immunocompromised patients suspected to have an infection. Data on pharmacokinetics (PK) of meropenem in patients with haematological malignancies are scarce.

Objectives: To optimize dosing regimens, we aimed to develop a PK population model for meropenem in this population.